8-K Announcements
6Material company update
May 5, 2026·SEC
Material company update
May 5, 2026·SEC
Material company update
Apr 13, 2026·SEC
IDEAYA Biosciences, Inc.(IDYA)Earnings, Financials & Key Ratios
IDYA•NASDAQ
Price updated Jun 19, 2026
AboutIDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase I clinical trial for patients with solid tumors having methylthioadenosine phosphorylase deletions; and IDE196, a protein kinase C inhibitor that is in Phase I/II clinical trial for genetically defined cancers having GNAQ or GNA11 gene mutations. Its preclinical pipeline includes various synthetic lethality programs targeting PARG inhibitor in tumors for patients having tumors with a defined biomarker based on genetic mutations and/or molecular signatures; Pol Theta inhibitors in tumors with BRCA or other homologous recombination deficiency mutations; and WRN inhibitors in tumors with high microsatellite instability. The company has a research collaboration agreement with Cancer Research UK and the University of Manchester to develop small molecule inhibitors of Poly (ADP-ribose) glycohydrolase; and a clinical trial collaboration and supply agreement with Pfizer Inc. for Phase I/II study in metastatic uveal melanoma, skin melanoma, and other solid tumors, as well as a strategic partnership with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.Show more
- Revenue$219M+3024.4%
- EBITDA-$155M+52.1%
- Net Income-$114M+58.6%
- EPS (Diluted)-1.28+61.9%
- Gross Margin97.9%+116.5%
- EBITDA Margin-70.74%+98.5%
- Operating Margin-72.84%+98.4%
- Net Margin-51.99%+98.7%
- ROE-10.92%+66.6%
IDYA Key Insights
IDEAYA Biosciences, Inc. (IDYA) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Strong 5Y sales CAGR of 62.1%
✗Weaknesses
- ✗Profits declining 26.9% over 5 years
- ✗Negative free cash flow
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when IDYA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
IDYA Price & Volume
IDEAYA Biosciences, Inc. (IDYA) stock price & volume — 10-year historical chart
Loading chart...
IDYA Growth Metrics
IDEAYA Biosciences, Inc. (IDYA) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years62.11%
3 Years62.54%
TTM3118.14%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM54.28%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM55.43%
Return on Capital
10 Years-38.29%
5 Years-23.17%
3 Years-26.97%
Last Year-14.97%
IDYA Recent Earnings
IDEAYA Biosciences, Inc. (IDYA) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 5/12 qtrs (42%)●Beat Revenue 5/12 qtrs (71%)
Q2 2026Latest
May 5, 2026Metric
Actual
Est
EPS
$1.11-3.7%
$1.07
Rev
$7M+30.2%
$5M
Q1 2026
Feb 17, 2026Metric
Actual
Est
EPS
$0.94+1.2%
$0.95
Rev
$11M+72.5%
$6M
Q4 2025
Nov 4, 2025Metric
Actual
Est
EPS
$1.33+240.6%
$0.95
Rev
$208M+3395.1%
$6M
Q3 2025
Aug 5, 2025Metric
Actual
Est
EPS
$0.88-3.5%
$0.85
Rev
—
$2M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 5, 2026 | $1.11vs $1.07-3.7% | $7Mvs $5M+30.2% |
| Q1 2026 | Feb 17, 2026 | $0.94vs $0.95+1.2% | $11Mvs $6M+72.5% |
| Q4 2025 | Nov 4, 2025 | $1.33vs $0.95+240.6% | $208Mvs $6M+3395.1% |
| Q3 2025 | Aug 5, 2025 | $0.88vs $0.85-3.5% | —vs $2M |
Based on last 12 quarters of dataView full earnings history →
IDYA Peer Comparison
IDEAYA Biosciences, Inc. (IDYA) competitors in Oncology Therapeutics Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 TPVG | 202.99M | 5.00 | 4.10 | 36.55% | -19.55% | -3.39% | 1.33 | |
 AGEN | 124.93M | 3.00 | -882.35 | 10.37% | 52.16% | |||
 IMVT | 7.26B | 35.34 | -12.76 | -68.16% | 0.00 | |||
 KYMR | 7.38B | 90.43 | -24.51 | -16.72% | -6.12% | -25.02% | 0.05 | |
 PRAX | 8.15B | 282.31 | -20.94 | -100% | -43.02% | 0.00 | ||
 PMVP | 60.26M | 1.13 | -0.76 | -68.98% | 0.01 | |||
 TNGX | 3.25B | 27.97 | -32.15 | 48.29% | -188.15% | -41.54% | 0.10 | |
 MGNX | 262.52M | 4.13 | -3.50 | 0.78% | -44.79% | -147.8% | 1.92 |
Compare IDYA vs Peers
IDEAYA Biosciences, Inc. (IDYA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
IDYA Income Statement
IDEAYA Biosciences, Inc. (IDYA) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 0 | 19.54M | 27.94M | 50.93M | 23.39M | 7M | 218.71M | 225.27M |
Revenue Growth % | - | - | - | - | 43.01% | 82.28% | -54.08% | -70.07% | 3024.43% | 3118.14% |
Cost of Goods Sold | 391K | 886K | 1.25M | 1.38M | 1.73M | 2.1M | 4.01M | 3.83M | 4.59M | 1.14M |
COGS % of Revenue | - | - | - | 7.07% | 6.17% | 4.13% | 17.14% | 54.77% | 2.1% | - |
Gross Profit | -391K▲ 0% | -886K▼ 126.6% | -1.25M▼ 40.5% | 18.16M▲ 1558.4% | 26.22M▲ 44.4% | 48.83M▲ 86.3% | 19.38M▼ 60.3% | 3.17M▼ 83.7% | 214.12M▲ 6663.0% | 224.13M▲ 0% |
Gross Margin % | - | - | - | 92.93% | 93.83% | 95.87% | 82.86% | 45.23% | 97.9% | 99.49% |
Gross Profit Growth % | - | -126.6% | -40.52% | 1558.39% | 44.39% | 86.26% | -60.32% | -83.66% | 6663.01% | - |
Operating Expenses | 14.05M | 35.53M | 43.03M | 53.5M | 76.48M | 111.33M | 153.81M | 330.14M | 373.43M | 407.6M |
OpEx % of Revenue | - | - | - | 273.83% | 273.73% | 218.59% | 657.71% | 4716.3% | 170.74% | - |
Selling, General & Admin | 1.66M | 3.78M | 8.71M | 13.8M | 18.33M | 21.8M | 24.3M | 35.47M | 63.32M | 69.19M |
SG&A % of Revenue | - | - | - | 70.65% | 65.59% | 42.8% | 103.9% | 506.69% | 28.95% | - |
Research & Development | 12.38M | 31.75M | 34.32M | 39.7M | 58.16M | 89.54M | 129.51M | 294.67M | 314.7M | 339.54M |
R&D % of Revenue | - | - | - | 203.18% | 208.15% | 175.8% | 553.81% | 4209.61% | 143.89% | - |
Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -4.59M | -1000K |
Operating Income | -14.44M▲ 0% | -36.42M▼ 152.2% | -44.27M▼ 21.6% | -35.34M▲ 20.2% | -50.27M▼ 42.2% | -62.5M▼ 24.3% | -134.43M▼ 115.1% | -326.98M▼ 143.2% | -159.31M▲ 51.3% | -183.47M▲ 0% |
Operating Margin % | - | - | - | -180.9% | -179.91% | -122.72% | -574.85% | -4671.07% | -72.84% | -81.44% |
Operating Income Growth % | - | -152.23% | -21.57% | 20.16% | -42.23% | -24.34% | -115.08% | -143.23% | 51.28% | - |
EBITDA | -14.05M | -35.53M | -43.03M | -33.96M | -48.54M | -60.4M | -130.42M | -323.14M | -154.72M | -178.87M |
EBITDA Margin % | - | - | - | -173.83% | -173.73% | -118.59% | -557.71% | -4616.3% | -70.74% | -79.4% |
EBITDA Growth % | - | -152.94% | -21.09% | 21.06% | -42.93% | -24.43% | -115.93% | -147.77% | 52.12% | 49.82% |
D&A (Non-Cash Add-back) | 391K | 886K | 1.25M | 1.38M | 1.73M | 2.1M | 4.01M | 3.83M | 4.59M | 4.6M |
EBIT | -11.86M | -34.35M | -41.98M | -34.49M | -49.76M | -58.66M | -112.96M | -274.48M | -159.31M | -183.47M |
Net Interest Income | 150K | 1.99M | 2.29M | 849K | 506K | 3.85M | 21.47M | 52.5M | 45.62M | 43.41M |
Interest Income | 150K | 1.99M | 2.29M | 849K | 506K | 3.85M | 21.47M | 52.5M | 45.62M | 43.41M |
Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Income/Expense | 2.58M | 2.07M | 2.3M | 849K | 506K | 3.85M | 21.47M | 52.5M | 45.62M | 43.41M |
Pretax Income | -11.86M▲ 0% | -34.35M▼ 189.5% | -41.98M▼ 22.2% | -34.49M▲ 17.8% | -49.76M▼ 44.3% | -58.66M▼ 17.9% | -112.96M▼ 92.6% | -274.48M▼ 143.0% | -113.7M▲ 58.6% | -140.06M▲ 0% |
Pretax Margin % | - | - | - | -176.55% | -178.1% | -115.17% | -483.05% | -3921.1% | -51.99% | -62.17% |
Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Net Income | -11.86M▲ 0% | -34.35M▼ 189.5% | -41.98M▼ 22.2% | -34.49M▲ 17.8% | -49.76M▼ 44.3% | -58.66M▼ 17.9% | -112.96M▼ 92.6% | -274.48M▼ 143.0% | -113.7M▲ 58.6% | -140.06M▲ 0% |
Net Margin % | - | - | - | -176.55% | -178.1% | -115.17% | -483.05% | -3921.1% | -51.99% | -62.17% |
Net Income Growth % | - | -189.55% | -22.21% | 17.82% | -44.26% | -17.87% | -92.59% | -142.98% | 58.58% | 54.28% |
Net Income (Continuing) | -11.86M | -34.35M | -41.98M | -34.49M | -49.76M | -58.66M | -112.96M | -274.48M | -113.7M | -140.06M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -0.83▲ 0% | -2.41▼ 190.4% | -1.90▲ 21.2% | -1.31▲ 31.1% | -1.41▼ 7.6% | -1.42▼ 0.7% | -1.96▼ 38.0% | -3.36▼ 71.4% | -1.28▲ 61.9% | -1.58▲ 0% |
EPS Growth % | - | -190.36% | 21.16% | 31.05% | -7.63% | -0.71% | -38.03% | -71.43% | 61.9% | 55.43% |
EPS (Basic) | -0.83 | -2.41 | -1.90 | -1.31 | -1.41 | -1.42 | -1.96 | -3.36 | -1.28 | - |
Diluted Shares Outstanding | 14.24M | 14.24M | 20.23M | 24.72M | 35.25M | 41.44M | 57.52M | 81.68M | 88.49M | 88.7M |
Basic Shares Outstanding | 14.24M | 14.24M | 20.23M | 24.72M | 35.25M | 41.44M | 57.52M | 81.68M | 88.49M | 88.7M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
IDYA Balance Sheet
IDEAYA Biosciences, Inc. (IDYA) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 13.58M | 90.67M | 101.65M | 288.61M | 251M | 370.45M | 532.63M | 689.71M | 666.73M | 696.11M |
Cash & Short-Term Investments | 13.16M | 89.96M | 98.96M | 283.58M | 246.77M | 364.83M | 525.11M | 676.32M | 639.39M | 671.2M |
Cash Only | 5.96M | 20.5M | 34.07M | 72.04M | 92.05M | 68.63M | 157.02M | 84.38M | 112.83M | 157.52M |
Short-Term Investments | 7.2M | 69.46M | 64.89M | 211.55M | 154.72M | 296.2M | 368.1M | 591.94M | 526.56M | 513.68M |
Accounts Receivable | 0 | 0 | 0 | 1.88M | 1.1M | 211K | 18K | 3K | 0 | 0 |
Days Sales Outstanding | - | - | - | 35.07 | 14.41 | 1.51 | 0.28 | 0.16 | - | 2.42 |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
Other Current Assets | 0 | 0 | 0 | 0 | 0 | 5.41M | 7.5M | 13.39M | 27.34M | 24.91M |
Total Non-Current Assets | 3.9M | 5.87M | 11.35M | 9.66M | 130.35M | 17.52M | 116.68M | 434.38M | 442.6M | 334.24M |
Property, Plant & Equipment | 3.74M | 5.15M | 9.7M | 9.48M | 8.66M | 8.99M | 8.41M | 27.74M | 31.29M | 31.25M |
Fixed Asset Turnover | - | - | - | 2.06x | 3.23x | 5.66x | 2.78x | 0.25x | 6.99x | 7.10x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 71K | 0 | 1.53M | 0 | 121.29M | 8.32M | 107.49M | 405.83M | 0 | 1.08B |
Other Non-Current Assets | 89K | 722K | 122K | 188K | 397K | 205K | 782K | 805K | 411.31M | 302.99M |
Total Assets | 17.48M▲ 0% | 96.54M▲ 452.3% | 113M▲ 17.0% | 298.27M▲ 164.0% | 381.35M▲ 27.9% | 387.97M▲ 1.7% | 649.32M▲ 67.4% | 1.12B▲ 73.1% | 1.11B▼ 1.3% | 1.03B▲ 0% |
Asset Turnover | - | - | - | 0.07x | 0.07x | 0.13x | 0.04x | 0.01x | 0.20x | 0.21x |
Asset Growth % | - | 452.33% | 17.05% | 163.95% | 27.85% | 1.74% | 67.36% | 73.12% | -1.31% | -5.17% |
Total Current Liabilities | 2.43M | 5.41M | 6.94M | 38.64M | 45.16M | 31.72M | 27.1M | 46.07M | 58.81M | 64.83M |
Accounts Payable | 662K | 1.42M | 709K | 953K | 2.1M | 4.28M | 6.6M | 15.42M | 17.58M | 20.74M |
Days Payables Outstanding | 617.98 | 583.75 | 207.86 | 251.88 | 444.35 | 743.55 | 600.87 | 1.47K | 1.4K | 5.91K |
Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 339K | 350K |
Deferred Revenue (Current) | 297K | 0 | 0 | 27.61M | 29.04M | 8.57M | 0 | 0 | 0 | 0 |
Other Current Liabilities | 728K | 413K | 63K | 18K | 0 | 0 | 11.78M | 30.35M | 40.89M | 43.74M |
Current Ratio | 5.58x | 16.75x | 14.65x | 7.47x | 5.56x | 11.68x | 19.65x | 14.97x | 11.34x | 10.74x |
Quick Ratio | 5.58x | 16.75x | 14.65x | 7.47x | 5.56x | 11.68x | 19.65x | 14.97x | 11.34x | 10.74x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | -5.91K |
Total Non-Current Liabilities | 30.78M | 140.08M | 5.66M | 61.35M | 34.67M | 6.8M | 1.13M | 18.87M | 27.57M | 28.25M |
Long-Term Debt | 3.21M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 27.57M | 28.25M |
Capital Lease Obligations | 0 | 0 | 5.63M | 5.18M | 3.48M | 1.61M | 1.13M | 18.87M | 0 | 80.77M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 27.58M | 140.08M | 34K | 12K | 0 | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 33.22M | 145.49M | 12.6M | 100M | 79.83M | 38.51M | 28.23M | 64.94M | 86.39M | 93.08M |
Total Debt | 3.21M | 0 | 6.77M | 6.72M | 5.18M | 3.48M | 2.87M | 19.17M | 27.91M | 28.6M |
Net Debt | -2.75M | -20.5M | -27.3M | -65.31M | -86.86M | -65.15M | -154.15M | -65.21M | -84.91M | -128.92M |
Debt / Equity | - | - | 0.07x | 0.03x | 0.02x | 0.01x | 0.00x | 0.02x | 0.03x | 0.03x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.16x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 0.72x |
Interest Coverage | - | - | - | - | - | - | - | - | - | - |
Total Equity | -15.74M▲ 0% | -48.95M▼ 211.0% | 100.4M▲ 305.1% | 198.27M▲ 97.5% | 301.51M▲ 52.1% | 349.45M▲ 15.9% | 621.09M▲ 77.7% | 1.06B▲ 70.5% | 1.02B▼ 3.4% | 937.27M▲ 0% |
Equity Growth % | - | -211% | 305.12% | 97.48% | 52.07% | 15.9% | 77.73% | 70.53% | -3.42% | -16.38% |
Book Value per Share | -1.11 | -3.44 | 4.96 | 8.02 | 8.55 | 8.43 | 10.80 | 12.97 | 11.56 | 10.57 |
Total Shareholders' Equity | -15.74M | -48.95M | 100.4M | 198.27M | 301.51M | 349.45M | 621.09M | 1.06B | 1.02B | 937.27M |
Common Stock | 1K | 0 | 2K | 3K | 4K | 5K | 7K | 9K | 9K | 9K |
Retained Earnings | -16.17M | -50.52M | -92.49M | -126.99M | -176.75M | -235.4M | -348.36M | -622.84M | -736.54M | -835.08M |
Treasury Stock | -431K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -1K | -31K | 65K | 7K | -712K | -2.87M | 562K | 812K | 2.27M | -494K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
IDYA Cash Flow Statement
IDEAYA Biosciences, Inc. (IDYA) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -12.22M | -27.62M | -39.31M | 55.46M | -55.78M | -87.17M | -115.22M | -247.58M | -71.1M | -85.93M |
Operating CF Margin % | - | - | - | 283.87% | -199.63% | -171.16% | -492.73% | -3536.91% | -32.51% | - |
Operating CF Growth % | - | -125.95% | -42.34% | 241.08% | -200.57% | -56.29% | -32.18% | -114.87% | 71.28% | 299.9% |
Net Income | -11.86M | -34.35M | -41.98M | -34.49M | -49.76M | -58.66M | -112.96M | -274.48M | -113.7M | -140.06M |
Depreciation & Amortization | 391K | 886K | 1.25M | 1.38M | 1.73M | 2.1M | 4.01M | 3.83M | 4.59M | 4.6M |
Stock-Based Compensation | 136K | 950K | 2.17M | 3.61M | 8.24M | 11.63M | 18.49M | 34.75M | 0 | 24.09M |
Deferred Taxes | -27K | -873K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | -2.43M | 4.11M | -467K | 562K | 1.83M | -695K | -11.55M | -23.23M | 36.14M | 18.92M |
Working Capital Changes | 1.56M | 1.65M | -284K | 84.41M | -17.81M | -41.55M | -13.21M | 11.55M | 1.87M | 6.53M |
Change in Receivables | 0 | 0 | 0 | -1.88M | 774K | 892K | 193K | 15K | 0 | 0 |
Change in Inventory | 0 | 0 | 0 | 2.29M | 3.79M | 0 | 0 | 0 | 0 | 0 |
Change in Payables | 254K | 322K | -195K | 225K | 1.17M | 1.86M | 2.63M | 8.28M | 2.7M | 3.02M |
Cash from Investing | -8.93M | -63.18M | 2.27M | -146.24M | -69.67M | -33.4M | -158.46M | -502.56M | 69.98M | 109.11M |
Capital Expenditures | -1.76M | -1.71M | -1.35M | -493K | -2.64M | -3.44M | -2.37M | -3.86M | -2.37M | -2M |
CapEx % of Revenue | - | - | - | 2.52% | 9.46% | 6.76% | 10.13% | 55.1% | 1.08% | 0.89% |
Acquisitions | 0 | 0 | -8K | -18K | 67.02M | 33.4M | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 0 | 0 | 8K | 18K | -67.02M | -33.4M | 0 | 0 | 0 | 0 |
Cash from Financing | 17.49M | 105.38M | 50.61M | 128.75M | 145.45M | 97.17M | 362.72M | 677.55M | 29.78M | 4.82M |
Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Equity Issued (Net) | 17.26M | 105.36M | 50.32M | 127.23M | 143.25M | 94.96M | 351.94M | 663.63M | 29.78M | 4.82M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 226K | 20K | 289K | 1.52M | 2.2M | 2.2M | 10.77M | 13.92M | 0 | 0 |
Net Change in Cash | -3.66M▲ 0% | 14.58M▲ 498.2% | 13.56M▼ 7.0% | 37.97M▲ 180.0% | 20.01M▼ 47.3% | -23.41M▼ 217.0% | 89.04M▲ 480.3% | -72.59M▼ 181.5% | 28.45M▲ 139.2% | 27.53M▲ 0% |
Free Cash Flow | -13.98M▲ 0% | -29.33M▼ 109.8% | -40.67M▼ 38.7% | 54.97M▲ 235.2% | -58.42M▼ 206.3% | -90.62M▼ 55.1% | -117.59M▼ 29.8% | -251.44M▼ 113.8% | -73.47M▲ 70.8% | -87.93M▲ 0% |
FCF Margin % | - | - | - | 281.35% | -209.09% | -177.92% | -502.85% | -3592.01% | -33.59% | -39.03% |
FCF Growth % | - | -109.77% | -38.66% | 235.17% | -206.28% | -55.11% | -29.77% | -113.82% | 70.78% | 67.19% |
FCF per Share | -0.98 | -2.06 | -2.01 | 2.22 | -1.66 | -2.19 | -2.04 | -3.08 | -0.83 | -0.99 |
FCF Conversion (FCF/Net Income) | 1.03x | 0.80x | 0.94x | -1.61x | 1.12x | 1.49x | 1.02x | 0.90x | 0.63x | 0.63x |
Interest Paid | 0 | 99K | 91K | 82K | 71K | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 1K | 1K | 1K | 4K | 0 | 0 | 0 | 0 | 0 |
IDYA Key Ratios
IDEAYA Biosciences, Inc. (IDYA) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | - | -163.16% | -23.1% | -19.91% | -18.02% | -23.28% | -32.67% | -10.92% | -13.96% |
Return on Invested Capital (ROIC) | - | -1818.36% | -25.73% | -21.69% | -18.79% | -26.84% | -33.57% | -12.37% | -15.88% |
Gross Margin | - | - | 92.93% | 93.83% | 95.87% | 82.86% | 45.23% | 97.9% | 99.49% |
Net Margin | - | - | -176.55% | -178.1% | -115.17% | -483.05% | -3921.1% | -51.99% | -62.17% |
Debt / Equity | - | 0.07x | 0.03x | 0.02x | 0.01x | 0.00x | 0.02x | 0.03x | 0.03x |
FCF Conversion | 0.80x | 0.94x | -1.61x | 1.12x | 1.49x | 1.02x | 0.90x | 0.63x | 0.63x |
Revenue Growth | - | - | - | 43.01% | 82.28% | -54.08% | -70.07% | 3024.43% | 3118.14% |
Related:IDYA Dividend History·IDYA Revenue History·IDYA Price History·IDYA P/E History·IDYA Financial Ratios·IDYA Institutional Holders
IDYA SEC Filings & Documents
IDEAYA Biosciences, Inc. (IDYA) SEC filings — annual & quarterly reports (10-K, 10-Q)
IDYA Frequently Asked Questions
IDEAYA Biosciences, Inc. (IDYA) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
IDEAYA Biosciences, Inc. (IDYA) reported $225.3M in revenue for fiscal year 2025.
IDEAYA Biosciences, Inc. (IDYA) grew revenue by 3024.4% over the past year. This is strong growth.
IDEAYA Biosciences, Inc. (IDYA) reported a net loss of $140.1M for fiscal year 2025.
Dividend & Returns
IDEAYA Biosciences, Inc. (IDYA) has a return on equity (ROE) of -10.9%. Negative ROE indicates the company is unprofitable.
IDEAYA Biosciences, Inc. (IDYA) had negative free cash flow of $87.9M in fiscal year 2025, likely due to heavy capital investments.